Literature DB >> 11317250

Herpes zoster in older adults.

K Schmader1.   

Abstract

Herpes zoster (HZ) strikes millions of older adults annually worldwide and disables a substantial number of them via postherpetic neuralgia (PHN). Key age-related clinical, epidemiological, and treatment features of zoster and PHN are reviewed. HZ is caused by renewed replication and spread of varicella-zoster virus (VZV) in sensory ganglia and afferent peripheral nerves in the setting of age-related, disease-related, and drug-related decline in cellular immunity to VZV. VZV-induced neuronal destruction and inflammation causes the principal problems of pain, interference with activities of daily living, and reduced quality of life in elderly patients. Recently, attempts to reduce or eliminate HZ pain have been bolstered by the findings of clinical trials that antiviral agents and corticosteroids are effective treatment for HZ and that tricyclic antidepressants, topical lidocaine, gabapentin, and opiates are effective treatment for PHN. Although these advances have helped, PHN remains a difficult condition to prevent and treat in many elderly patients.

Entities:  

Mesh:

Year:  2001        PMID: 11317250     DOI: 10.1086/320169

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  74 in total

1.  Tracing thymic output in older individuals.

Authors:  W A Mitchell; P O Lang; R Aspinall
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

2.  Dementia following herpes zoster encephalitis.

Authors:  Katherine J Bangen; Lisa Delano-Wood; Christina E Wierenga; Nikki H Stricker; John R Hesselink; Mark W Bondi
Journal:  Clin Neuropsychol       Date:  2010-05-24       Impact factor: 3.535

Review 3.  Chickenpox, chickenpox vaccination, and shingles.

Authors:  P D Welsby
Journal:  Postgrad Med J       Date:  2006-05       Impact factor: 2.401

Review 4.  Herpes zoster and the search for an effective vaccine.

Authors:  N Arnold; I Messaoudi
Journal:  Clin Exp Immunol       Date:  2016-07-25       Impact factor: 4.330

Review 5.  Zoster vaccine live (Oka/Merck).

Authors:  Dean M Robinson; Caroline M Perry
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers.

Authors:  Helen S Pentikis; Mark Matson; George Atiee; Brian Boehlecke; Jeff T Hutchins; Joseph M Patti; Geoffrey W Henson; Amy Morris
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

Review 7.  Reducing the burden of Herpes Zoster in Italy.

Authors:  Giovanni Gabutti; Elisabetta Franco; Paolo Bonanni; Michele Conversano; Antonio Ferro; Marzia Lazzari; Stefania Maggi; Alessandro Rossi; Silvestro Scotti; Francesco Vitale; Antonio Volpi; Donato Greco
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

8.  The burden of disease of Herpes Zoster in Tuscany.

Authors:  Miriam Levi; Irene Bellini; Leonardo Capecchi; Luca Pieri; Angela Bechini; Sara Boccalini; Silvia Callaioli; Roberto Gasparini; Donatella Panatto; Emilia Tiscione; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

9.  Attenuation of the adaptive immune response in rhesus macaques infected with simian varicella virus lacking open reading frame 61.

Authors:  Christine Meyer; Amelia Kerns; Kristen Haberthur; Jesse Dewane; Joshua Walker; Wayne Gray; Ilhem Messaoudi
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

10.  IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies.

Authors:  G N Malavige; L T Rohanachandra; L Jones; L Crack; M Perera; N Fernando; D Guruge; G S Ogg
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.